Health News
FONT-SIZE Plus   Neg
Share SHARE

Second-Choice Lymphoma Drug Found Less Effective On Kids

Second-Choice Lymphoma Drug Found Less Effective On Kids

The Hodgkin lymphoma drug known as cyclophosphamide (Cytoxan) may be significantly less effective for children, says a new study from researchers at the St. Jude Children's Research Hospital in Memphis, Tennessee. For the study they examined instances in which Cytoxan was adopted for treatment after the industry standard mechlorethamine (Mustargen) became unavailable.

They found that children who began taking the drug as a second option saw a 75 percent rate of event-free survival over two years. This is compared to an 88 percent rate with Mustargen.

"Our results suggest that even promising substitute regimens should be examined carefully before adoption; what might appear to be a suitable alternative regimen may result in an inferior outcome -- an intolerable situation for young people with curable diseases," the researchers wrote of their findings.

Their data appears in the December 27 issue of the New England Journal of Medicine.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Health News

comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.